TickerKhojPharmaceuticals · Pharmaceuticals: Other · NSE: GRANULES · data 2026-11-02
Granules India Limited
In plain words
Price: 9.6% below its 52-week high of ₹923.65.
Delivery: 50.7% of traded shares were kept for delivery over the last 10 sessions, against 51.1% over the last 60.
Latest results: a net profit of ₹180 cr for the quarter ended Jun 2026 (+63.0% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹5,632 cr |
| Net profit (last 12 months) | ₹662 cr |
| Sales growth, 3 years (yearly) | 5.9% |
| Profit growth, 3 years (yearly) | 4.8% |
At a glance
Promoters 37.4% (-1.4 pts in a year), pledged 0.0%, institutions 35.6%.
P/E 31.0, dividend yield 0.2%. Price relative to earnings and book value (low is cheaper, not better).
ROE 13.5%, ROCE 17.9%, operating margin 17.2%: how much profit it earns on the money it uses.
Debt/equity 0.30, Profit growth 4.8% and sales growth 5.9% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Promoters cut their holding by 1.4 points in a year.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
Q1 FY27
Revenue: 1476.77
Net Profit: 179.96
Operating Margin: 22.9
EPS: 7.26
Q1 FY27
राजस्व: 1476.77
नेट लाभ: 179.96
परिचालन मार्जिन: 22.9
EPS: 7.26
Q1 FY27
મહેસૂલ: 1476.77
નેટ લાભ: 179.96
કાર્યકારી માર્જિન: 22.9
EPS: 7.26
Written by AI from the filed numbers and checked against them. Not a recommendation.
Smart-money activity
28/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 49.5% over the last 20 sessions vs 52.7% in the 40 before (0.94x); shares delivered per day 0.62x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: Net −₹348.64 cr in bulk/block deals over 90 days (0 net buying days, 1 net selling day): more sold than bought.
- Insider / SAST buys 6/15: 0 insider buy days (promoter group among them) and 1 SAST acquisition day in 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 9/15: 12 schemes hold it, about ₹432 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 8/15: Verdict "Building", sustained score 55/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Insider ● Deal ● Dividend ● Results
- 5 Oct 26Insider SAST disclosure: Uma Devi Chigurupati acquired 2,48,80,342 shares +1.8% next session
- 11 Sept 26Deal Block deal: 360 ONE PIPE FUND +3 bought ₹1,160 cr (net ₹0 cr) -3.0% next session
- 11 Sept 26Deal Bulk deal: KRISHNA PRASAD CHIGURUPATI sold ₹348.64 cr -3.0% next session
- 30 Jul 26Dividend Dividend ₹1.75 (ex-date) -2.0% next session
- 21 Jul 26Results Q1 FY27 results: profit +63.0% YoY -2.5% next session
- 29 Apr 26Results Q4 FY26 results: profit +32.6% YoY -0.8% next session
- 23 Jan 26Results Q3 FY26 results: profit +27.7% YoY +1.4% next session
- 13 Nov 25Results Q2 FY26 results: profit +34.3% YoY +1.1% next session
- 12 Aug 25Results Q1 FY26 results: profit −18.0% YoY +4.5% next session
- 31 Jul 25Dividend Dividend ₹1.5 (ex-date) -8.2% next session
- 28 May 25Results Q4 FY25 results: profit +17.3% YoY +1.2% next session
- 24 Jan 25Results Q3 FY25 results: profit −6.4% YoY -9.2% next session
- 6 Nov 24Results Q2 FY25 results: profit −4.8% YoY +3.9% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹1,477 cr | ₹180 cr | +63.0% | 22.9% | 7.26 |
| Mar 2026 | ₹1,471 cr | ₹202 cr | +32.6% | 23.9% | 8.23 |
| Dec 2025 | ₹1,388 cr | ₹150 cr | +27.7% | 22.2% | 6.19 |
| Sept 2025 | ₹1,297 cr | ₹131 cr | +34.3% | 21.5% | 5.38 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 37.39% | 38.02% | 38.02% | 38.82% |
| Foreign institutions (FII) | 20.25% | 17.50% | 15.31% | 13.55% |
| Domestic institutions (DII) | 15.33% | 16.11% | 17.01% | 17.48% |
| Mutual funds | 4.26% | 3.45% | 2.85% | 5.35% |
| Retail investors | 12.68% | 14.17% | 14.32% | 14.51% |
| Number of shareholders | 1,82,022 | 1,69,422 | 1,60,286 | 1,63,184 |
Common questions
What was Granules India Limited's latest quarterly profit?
Granules India Limited reported a net profit of ₹180 cr for the quarter ended Jun 2026 (+63.0% on the same quarter a year earlier), on revenue of ₹1,477 cr.
How much do promoters hold in Granules India Limited?
Promoters held 37.39% of Granules India Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Granules India Limited debt-free?
Its latest reported debt-to-equity ratio is 0.3.
What is Granules India Limited's P/E ratio?
About 31, based on the last 12 months' earnings and a price of ₹834.9 (data 2026-11-02).
What is the 52-week high and low of Granules India Limited?
The 52-week high is ₹923.65 and the 52-week low is ₹529.85.
Mutual funds holding Granules India Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 12 schemes holding about ₹432 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| ADITYA BIRLA SUN LIFE MULTI-CAP FUND | Aditya Birla Sun Life Mutual Fund | 1.87% | ₹136 cr |
| ADITYA BIRLA SUN LIFE SMALL CAP FUND | Aditya Birla Sun Life Mutual Fund | 1.96% | ₹120 cr |
| ADITYA BIRLA SUN LIFE VALUE FUND | Aditya Birla Sun Life Mutual Fund | 1.78% | ₹119 cr |
| Nippon India Nifty Smallcap 250 Index Fund | Nippon India Mutual Fund | 0.56% | ₹19 cr |
| Mirae Asset Nifty Smallcap 250 Momentum Quality 100 ETF | Mirae Asset Mutual Fund | 1.68% | ₹16 cr |
| SBI Nifty Smallcap 250 Index Fund | SBI Mutual Fund | 0.56% | ₹10 cr |
| Nippon India Nifty 500 Momentum 50 Index Fund | Nippon India Mutual Fund | 0.68% | ₹9 cr |
| Mirae Asset Nifty MidSmallcap400 Momentum Quality 100 ETF | Mirae Asset Mutual Fund | 0.67% | ₹3 cr |
| ADITYA BIRLA SUN LIFE BSE 500 MOMENTUM 50 INDEX FUND | Aditya Birla Sun Life Mutual Fund | 0.72% | ₹1 cr |
| Mirae Asset Nifty Smallcap 250 ETF | Mirae Asset Mutual Fund | 0.56% | ₹1 cr |
| Mirae Asset Nifty 500 Healthcare ETF | Mirae Asset Mutual Fund | 0.93% | ₹0 cr |
| SBI Nifty Small Cap 250 ETF | SBI Mutual Fund | 0.56% | ₹0 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Granules India Limited | ₹834.9 | ₹20,804 cr | 31 | — | 13.5% | 17.9% | 0.3 | +45.4% |
| Cipla Ltd | ₹1,382.9 | ₹1,11,486 cr | 38.6 | 3.2 | 11.8% | 14.5% | 0.02 | -8.4% |
| Aurobindo Pharma Ltd | ₹1,669.6 | ₹96,537 cr | 26.1 | — | 9.9% | 15.1% | 0.21 | +51.1% |
| Lupin Limited | ₹2,023.5 | ₹91,870 cr | 16.8 | — | 26.9% | 30.7% | 0.3 | +4.0% |
| Sudeep Pharma Limited | ₹1,082.1 | ₹12,048 cr | 64.9 | 12.8 | 25.1% | 28.4% | 0.17 | +48.2% |
| Amrutanjan Health Care Limited | ₹496.85 | ₹1,452 cr | 26.6 | — | 16.6% | 17.9% | 0 | -31.3% |
Compare GRANULES with CIPLA in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open GRANULES in TickerKhoj →